Barron takes on business development role

Eurofins AvTech Laboratories has appointed Michael Barron as director of business development.

Eurofins AvTech Laboratories, a US analytical contract research organisation (CRO), has appointed Michael Barron as director of business development.

Barron has previously worked for Catalent Pharma Solutions, Cardinal Health, and other leading contract drug development and analytical service companies.

AvTech offers analytical support for all stages of drug discovery and development from early ADME studies of drug candidates to stability and release testing of the finished product. The company places particular emphasis on the development, validation, and routine performance of GMP and GLP compliant methods.




You may also like

Research & Development

BioGenes and Eurofins Munich form HCP analysis partnership

BioGenes specialises in highly sophisticated and customized antibody and immunoassay development
Research & Development

Merck Millipore to sell Discovery and Development Solutions Business to Eurofins

DDS provides bioanalytical testing and early stage discovery services to the biopharmaceutical market
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part II)

Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations
Manufacturing

Kindeva to showcase complex drug delivery expertise at CPHI 2025

Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities
Subscribe now